share_log

Faron Pharmaceuticals Oy (LON:FARN) Stock Price Crosses Below Fifty Day Moving Average of $191.41

Faron Pharmaceuticals Oy (LON:FARN) Stock Price Crosses Below Fifty Day Moving Average of $191.41

Faron PharmPharmticals Oy(伦敦股票代码:FARN)股价跌破50日移动均线191.41美元
Defense World ·  2022/09/17 03:51

Faron Pharmaceuticals Oy (LON:FARN – Get Rating) passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 191.41 ($2.31) and traded as low as GBX 173 ($2.09). Faron Pharmaceuticals Oy shares last traded at GBX 185 ($2.24), with a volume of 44,154 shares trading hands.

在周五的交易中,Faron PharmPharmticals Oy(LON:FARN-GET评级)跌破了50日移动均线。该股的50日移动均线为191.41英镑(合2.31美元),交易价格低至173英镑(合2.09美元)。Faron PharmPharmticals Oy股票的最新交易价格为185英镑(合2.24美元),成交量为44,154股。

Faron Pharmaceuticals Oy Price Performance

Faron制药的OY价格表现

The firm has a fifty day moving average price of GBX 191.41 and a two-hundred day moving average price of GBX 213.68. The stock has a market capitalization of £102.24 million and a P/E ratio of -5.15. The company has a debt-to-equity ratio of 121.51, a quick ratio of 1.09 and a current ratio of 1.70.

该公司的50日移动均线价格为191.41英镑,200日移动均线价格为213.68英镑。该股市值为1.0224亿GB,市盈率为-5.15。该公司的债务权益比率为121.51,速动比率为1.09,流动比率为1.7。

Faron Pharmaceuticals Oy Company Profile

Faron制药公司简介

(Get Rating)

(获取评级)

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.

Faron PharmPharmticals Oy是一家临床阶段药物发现和开发公司。该公司开发了一系列基于免疫调节的专利候选药物,以满足未得到满足的需求,包括免疫肿瘤学、器官保护和再生医学。它的主要候选产品是Traumakine,一种静脉注射干扰素β-1a疗法,用于治疗急性呼吸窘迫综合征、新冠肺炎、急性肾损伤、心脏保护、实体器官移植和缺血再灌注损伤;以及Bexmarilimab,一种新的精密癌症免疫疗法候选药物,用于治疗实体瘤、非小细胞肺癌和血液系统恶性肿瘤。

Recommended Stories

推荐故事

  • 3 Banks Worth Considering For Q4
  • Stock Market: 3 Islands Of Strength In A Sea Of Red
  • No One Told These 3 Stocks It's a Down Week
  • Is There a Cure for What is Ailing Teladoc Stock?
  • MarketBeat: Week in Review 9/12 – 9/16
  • 第四季度值得考虑的3家银行
  • 股市:红海中的三座强国
  • 没有人告诉这三只股票这是下跌的一周
  • 有什么办法可以治愈Teladoc股票的问题吗?
  • MarketBeat:回顾一周9/12-9/16

Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.

接受Faron制药Oy Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Faron PharmPharmticals Oy和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发